QSAM News and Press, QSAM Biosciences Inc

QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...

2024-04-16 08:42:16 ET More on QSAM Biosciences QSAM to be acquired by Telix for $33.1M plus $90M CVR Financial information for QSAM Biosciences Read the full article on Seeking Alpha For further details see: QSAM Biosciences to implement a 1-for-2,000 re...

Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc . (OTCQB: QSAM) (“ QSAM ” or the “ Company ”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par...

2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...

QSAM Biosciences (OTCQB: QSAM) , a clinical-stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has signed a definitive agreement and plan of merger pr...

2024-02-07 16:23:47 ET More on QSAM Biosciences QSAM Biosciences signs term sheet to be acquired by Telix Pharmaceuticals Financial information for QSAM Biosciences Read the full article on Seeking Alpha For further details see: QSAM to be acquired by Tel...

Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited ...

QSAM Biosciences (OTCQB: QSAM) , a clinical-stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has signed a nonbinding term sheet with Telix Pharmaceu...

2023-11-14 07:56:20 ET More on QSAM Biosciences Financial information for QSAM Biosciences For further details see: QSAM Biosciences signs term sheet to be acquired by Telix Pharmaceuticals

Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and related conditions, has signed a non-binding term sheet (the “Term Sheet”) with Tel...